Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) – Pipeline Review, H2 2017’, provides in depth analysis on Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Infectious Disease, Musculoskeletal Disorders, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones and Toxicology under development targeting Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)

The report reviews Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics and enlists all their major and minor projects

The report assesses Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Biogen Inc

BioMAS Ltd

Factor Therapeutics Ltd

MedImmune LLC

Merck & Co Inc

Merck KGaA

Morphic Therapeutic Inc

SciFluor Life Sciences LLC

Vascular Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Overview 8

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Therapeutics Development 9

Products under Development by Stage of Development 9

Products under Development by Therapy Area 10

Products under Development by Indication 11

Products under Development by Companies 14

Products under Development by Universities/Institutes 17

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Therapeutics Assessment 19

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Companies Involved in Therapeutics Development 25

Biogen Inc 25

BioMAS Ltd 25

Factor Therapeutics Ltd 25

MedImmune LLC 26

Merck & Co Inc 26

Merck KGaA 27

Morphic Therapeutic Inc 27

SciFluor Life Sciences LLC 28

Vascular Pharmaceuticals Inc 28

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Drug Profiles 29

264-RAD - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

abituzumab - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

AC-301 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Antibodies to Integrin Inhibit Alpha V and Beta 6 for Oncology - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

AS-101 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

BG-00011 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

C-16Y - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

cilengitide - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

CWHM-12 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

MK-0429 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

MSP-68 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

OCU-200 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Melanoma - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Proagio - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Protein to Agonize Integrin Alpha V, Beta 3 and Beta 5 for Malabsorption Syndrome - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Recombinant Protein to Antagonize VEGFR2, ITGB3 and ITGAV for Oncology - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

RSF-201 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

SF-0166 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Small Molecule to Antagonize AlphaV and Beta6 for Fibrosis - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Small Molecules to Antagonize Integrin Alpha V and Beta 1 for Cardiovascular Disease - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Small Molecules to Antagonize Integrin Alpha V for Fibrosis - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecules to Antagonize Integrin Alpha V for Oncology - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

tetraiodothyroacetic acid - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

VF-001 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

VPI-2690B - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Dormant Products 60

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Discontinued Products 64

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Product Development Milestones 65

Featured News & Press Releases 65

Nov 02, 2017: VF001002 Clinical Trial Update: Strong performance in October driven by new sites 65

Oct 20, 2017: Pursuing Novel Pathways in Immunology: Merck Presents New Clinical Data on Abituzumab at 2017 ACR/ARHP Annual Meeting 65

Sep 28, 2017: SciFluor Announces Positive Results of Phase 1/2 Study of SF0166 Topical Ophthalmic Solution in Diabetic Macular Edema Patients 66

May 08, 2017: Ocugen Expands Global Patent Portfolio for OCU200 67

Apr 07, 2017: Factor Therapeutics: Phase II Clinical Trial Progress Update 68

Dec 20, 2016: Factor Therapeutics - First Patient In and Clinical Update 69

Nov 07, 2016: FDA Clinical Hold Lifted for IND 119526 (VF - 001) 69

Oct 17, 2016: SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution 70

Oct 10, 2016: Submission of IND Amendments for Phase II Study of VF - 001 in the US 70

Aug 03, 2016: Factor Therapeutics Announces Formation of Medical Advisory Board 71

Aug 01, 2016: SciFluor Life Sciences Enters Clinical Trial Stage for Novel Treatment for Retinal Diseases 73

May 31, 2016: New Class of Protein Could Treat Cancer and Other Diseases, Georgia State Researchers Find 73

May 25, 2016: Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology 74

Apr 02, 2016: Iceni Pharmaceuticals announces appointment of cilengitide inventor Prof. Dr. Horst Kessler to its Scientific Advisory Board 75

Mar 09, 2016: SciFluor Life Sciences Awarded Second U.S. Patent for Integrin avß3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease 75

Appendix 77

Methodology 77

Coverage 77

Secondary Research 77

Primary Research 77

Expert Panel Validation 77

Contact Us 77

Disclaimer 78

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Indications, H2 2017 11

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13

Number of Products under Development by Companies, H2 2017 14

Products under Development by Companies, H2 2017 15

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16

Number of Products under Investigation by Universities/Institutes, H2 2017 17

Products under Investigation by Universities/Institutes, H2 2017 18

Number of Products by Stage and Mechanism of Actions, H2 2017 20

Number of Products by Stage and Route of Administration, H2 2017 22

Number of Products by Stage and Molecule Type, H2 2017 24

Pipeline by Biogen Inc, H2 2017 25

Pipeline by BioMAS Ltd, H2 2017 25

Pipeline by Factor Therapeutics Ltd, H2 2017 26

Pipeline by MedImmune LLC, H2 2017 26

Pipeline by Merck & Co Inc, H2 2017 27

Pipeline by Merck KGaA, H2 2017 27

Pipeline by Morphic Therapeutic Inc, H2 2017 28

Pipeline by SciFluor Life Sciences LLC, H2 2017 28

Pipeline by Vascular Pharmaceuticals Inc, H2 2017 28

Dormant Products, H2 2017 60

Dormant Products, H2 2017 (Contd..1), H2 2017 61

Dormant Products, H2 2017 (Contd..2), H2 2017 62

Dormant Products, H2 2017 (Contd..3), H2 2017 63

Discontinued Products, H2 2017 64

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Top 10 Indications, H2 2017 11

Number of Products by Mechanism of Actions, H2 2017 19

Number of Products by Stage and Mechanism of Actions, H2 2017 19

Number of Products by Routes of Administration, H2 2017 21

Number of Products by Stage and Routes of Administration, H2 2017 21

Number of Products by Molecule Types, H2 2017 23

Number of Products by Stage and Molecule Types, H2 2017 23

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports